Jefferies analyst Kambiz Yazdi raised the firm’s price target on Werewolf Therapeutics to $15 from $12 and keeps a Buy rating on the shares. The firm believes early efficacy demonstrates proof of concept for WTX-124 and is “encouraged” that ‘124 maybe showing efficacy in cancer types different from rIL-2s approved indications. If WTX-330 also shows efficacy in the first half of 2024, Werewolf “may also demonstrate proof-of-platform, a rare feat in biotech,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HOWL:
- Werewolf present preliminary data from Phase 1/1b trial for WTX-124
- Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Werewolf abstract shows positive signals for WTX-124, says H.C. Wainwright
- Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Werewolf Therapeutics to present clinical, preclinical data at SITC meeting
